2017 Article Archive
First-in-class drug holds promise for therapy-resistant breast cancer
UT Southwestern Simmons Cancer Center researchers have shown that a first-in-class molecule can prevent breast cancer growth when traditional therapies stop working.
Study answers why ketamine helps depression, offers target for safer therapy
UT Southwestern Medical Center scientists have identified a key protein that helps trigger ketamine’s rapid antidepressant effects in the brain, a crucial step to developing alternative treatments to the controversial drug being dispensed in a growing number of clinics across the country.
The link between fat tissue and disease
Body fat can seem mysterious and confounding, but Dr. Philipp E. Scherer aims to unravel those mysteries – especially in regard to fat’s relationship with disease.
Top 5 news articles of 2017
Stories below from UT Southwestern’s Peter O’Donnell Jr. Brain Institute, Harold C. Simmons Comprehensive Cancer Center, UT Southwestern Medical School, and Obstetrics and Gynecology Department garnered the most mouse clicks during 2017.
UTSW police show a heart for the homeless
The inability to lend a tangible hand to homeless individuals had long bothered UTSW Police Cpl. Phillip Starr. That led him and other officers to assemble and hand out basic comfort kits for those in need.
How to cook up some healthy, hearty holiday foods
Learn how to make healthier versions of some favorite holiday foods – turkey, sweet potatoes, desserts, and more.
School of Health Professions graduates 124 at commencement
School of Health Professions graduates 124 at commencement
Sweet tips on how to limit sugar during the holidays
Tips on how to cut back on sugars during the holidays.
FDA-approved high blood pressure drug extends life span in roundworms
An FDA-approved drug to treat high blood pressure seems to extend life span in worms via a cell signaling pathway that may mimic caloric restriction.
New class of anti-cancer drug effective against kidney cancer
A novel drug belonging to a new class of medicines called HIF-2 inhibitors show promise in treating metastatic kidney cancer.